Metabolic comorbidities and male sex influence steatosis in chronic hepatitis C after viral eradication by direct-acting antiviral therapy (DAAs): Evaluation by the controlled attenuation parameter (CAP). Issue 10 (October 2021)

• Record Type: Journal Article
• Authors: Cespiati, Annalisa; Petta, Salvatore; Lombardi, Rosa; Di Marco, Vito; Calvaruso, Vincenza; Bertelli, Cristina; Pisano, Giuseppina; Fatta, Erika; Sigon, Giordano; Iuculano, Federica; Crapanzano, Luciano; Gibilaro, Gerlando; Francione, Paolo; Craxì, Antonio; Fargion, Silvia; Fracanzani, Anna Ludovica
• Is Part Of: Digestive and liver disease. Volume 53:Issue 10(2021)
• Page Start: 1301
• Page End: 1307
• Publication Date: 2021-10
• Subjects: Overweight -- Hypertriglyceridemia -- De novo steatosis -- Male sex -- HCV -- DAAs -- SVR; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; 616.33005
• DOI: 10.1016/j.dld.2020.11.001
• Languages: English
• ISSNs: 1590-8658

Abstract

Abstract: Background: Chronic hepatitis C (CHC) is associated with hepatic steatosis, related to both a direct viral action and metabolic features. Vice-versa data on hepatic steatosis after viral eradication by direct-acting antiviral agents (DAA) are undefined although the presence of metabolic alterations could strongly influence the occurrence of steatosis as in NAFLD. The controlled attenuation parameter (CAP) (FibroscanⓇ) allows the qualitative and quantitative evaluation of fatty liver. Aim: to evaluate in patients with CHC whether hepatic steatosis diagnosed by CAP modifies after DAAs-induced sustained virologic response (SVR). Methods: Data were collected the day of DAAs therapy starting and six months after SVR. CAP ≥ 248 dB/m defined the presence of steatosis. Results: 794 CHC SVR patients referring to 2 Italian Units were enrolled. Mean age was 64 ± 16 ys, 50% males, BMI 25.4 ± 4 kg/m 2, genotype type-1 in 73%, type-3 in 8%. Prevalence of hepatic steatosis at baseline was 32% by US and 46% by CAP. De novo steatosis developed in 125 (29%), resolution in 122 (30%). At multivariate analysis de novo steatosis was independently associated with male sex (OR 1.7, CI 95% 1.09–2.67; p = 0.02) and baseline BMI (for unit increase OR 1.19, CI 95%1.11–1.29; p < 0.001). Baseline BMI (for unit increase OR 0.47, CI 95% 0.25–0.89; p = 0.02) and triglycerides (for unit increase OR 0.93, CI 95% 0.87–0.99; p = 0.03) prevented steatosis resolution after therapy. Conclusions: after SVR de novo steatosis and resolution of baseline steatosis are closely related to the presence of metabolic comorbidities.